Last reviewed · How we verify
Adjuvanted, trivalent subunit influenza vaccine
Adjuvanted, trivalent subunit influenza vaccine is a Biologic drug developed by Seqirus. It is currently in Phase 1 development.
At a glance
| Generic name | Adjuvanted, trivalent subunit influenza vaccine |
|---|---|
| Sponsor | Seqirus |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Pain
- Redness
- Fatigue
- Swelling
- Headache
- Arthralgia
- Myalgia
- Ecchymosis
- Diarrhea
- Other
Key clinical trials
- Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012 (PHASE2)
- Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children. (PHASE3)
- Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses (PHASE4)
- A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity (NA)
- Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults (PHASE3)
- A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older (PHASE4)
- Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases. (PHASE2)
- Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvanted, trivalent subunit influenza vaccine CI brief — competitive landscape report
- Adjuvanted, trivalent subunit influenza vaccine updates RSS · CI watch RSS
- Seqirus portfolio CI
Frequently asked questions about Adjuvanted, trivalent subunit influenza vaccine
What is Adjuvanted, trivalent subunit influenza vaccine?
Adjuvanted, trivalent subunit influenza vaccine is a Biologic drug developed by Seqirus.
Who makes Adjuvanted, trivalent subunit influenza vaccine?
Adjuvanted, trivalent subunit influenza vaccine is developed by Seqirus (see full Seqirus pipeline at /company/seqirus).
What development phase is Adjuvanted, trivalent subunit influenza vaccine in?
Adjuvanted, trivalent subunit influenza vaccine is in Phase 1.
What are the side effects of Adjuvanted, trivalent subunit influenza vaccine?
Common side effects of Adjuvanted, trivalent subunit influenza vaccine include Pain, Redness, Fatigue, Swelling, Headache, Arthralgia.